Breaking Down Barriers in Cardiology Trials to Expand Access to At-Risk Populations

Discussions about access to clinical trials often focus on rare diseases, where patient availability is constrained from the outset. Yet the need for representative participation extends to every therapeutic area, including high-prevalence conditions, such as cardiovascular disease. Even in large, global cardiology programs with robust recruitment pipelines, securing balanced enrollment across relevant populations remains a persistent challenge. Ensuring that study participants reflect the full spectrum of individuals who will ultimately receive a therapy is essential for establishing both safety and real-world effectiveness.

The barriers to achieving this representation differ widely depending on the mechanism of action, the disease biology, and the demographics of the patient population. In cardiology, two gaps consistently stand out: limited participation by women and by racial and ethnic minorities. Both patterns have deep historical roots. Women have long been underdiagnosed in cardiovascular medicine, in part because their symptoms are frequently misattributed to gastrointestinal issues, stress, or anxiety. When an underlying cardiac condition is missed, the opportunity to refer a patient into a study is missed as well. This diagnostic gap is visible even in specific disease areas: at one of our sites running multiple cardiac amyloidosis studies, only two of more than 50 randomized patients were women, despite the disease affecting far more women in clinical practice.

Similar disparities appear in other conditions. Heart failure with preserved ejection fraction, for example, disproportionately affects women and certain minority groups yet is often misdiagnosed or attributed to aging, deconditioning, or respiratory issues. Arrhythmias, such as atrial fibrillation, are also detected later in some racial and ethnic minority populations, partly due to inconsistent access to specialty care and differences in how symptoms are reported or interpreted. These diagnostic blind spots further narrow the pool of patients ever considered for trial participation.

Minority participation faces a different set of obstacles. Many groups, including people of African, Afro-Caribbean, and South Asian descent, carry a significantly higher cardiovascular risk than white populations, yet their enrollment levels in clinical studies remain disproportionately low. A legacy of unethical research in the past continues to prevent the full establishment of trust in parts of the healthcare system, and this mistrust affects research participation as well. Cultural and linguistic mismatches between site personnel and local communities can further discourage engagement. At some locations, the lack of research staff who reflect the communities they serve limits the comfort level of prospective participants.

Socioeconomic pressures compound these issues. Even when travel reimbursement is offered, patients may not be able to pay costs upfront or take time away from work. These barriers are particularly acute in cardiology trials that involve frequent on-site procedures or monitoring requirements. Comorbidities add another layer of complexity: individuals from underserved or under-resourced communities often have less regular access to healthcare, making conditions like hypertension, diabetes, and renal disease more poorly controlled. As a result, they are more likely to fall outside strict inclusion and exclusion thresholds, unintentionally narrowing the pool of eligible participants.

Together, these factors illustrate why representation in cardiovascular research remains a consistent challenge. Increasing diversity is not simply a matter of expanding outreach; it requires recognizing how diagnostic pathways, historical experiences, socioeconomic realities, and comorbidity burdens shape the likelihood that any given patient will be invited — and able — to participate.

Improving representation in cardiovascular research begins with something fundamental: respect. For many patients, particularly those from communities with a history of being overlooked or mistreated in healthcare, respect is the starting point for trust. Even when a site team is not deeply familiar with a patient’s culture, genuine respect conveyed through careful listening, clear communication, and sensitivity to individual concerns can lower barriers that might otherwise prevent participation.

Building on this foundation requires deliberate investment in cultural awareness. Patient populations differ widely in language, customs, family dynamics, and expectations of the healthcare system. These nuances shape how people interpret medical information, how comfortable they feel in a clinical environment, and whether they view research as welcoming or alienating. Education for site staff on these cultural contexts enables conversations with potential participants that are accurate and culturally appropriate and affirming.

Practical elements of the trial experience matter as well. Recruitment materials and consent documents should be available in relevant languages and designed to reflect the diversity of the communities they aim to reach. Visual representation, tone, and accessibility all influence whether patients feel included. In some regions, sponsors or health systems provide translated consent forms or professional interpreter services, but availability varies, and gaps can have real consequences. As several investigators noted, patients who cannot read or understand consent documents may be excluded entirely — not because they are unwilling but because the study lacks the infrastructure to support them.

In many communities, the barrier extends beyond translation itself. Some patients may have limited literacy in any language or may feel uncomfortable signing documents they cannot fully interpret, even when verbal explanations are provided. Others may be hesitant to engage with formal paperwork due to prior negative experiences with institutions. Without alternative consent pathways, such as oral explanations supported by visual aids or assisted walkthroughs, interested patients may be unintentionally excluded because the research infrastructure has not adapted to their communication needs.

Culturally aligned communication also extends to nonverbal interactions and the broader environment. Some communities may welcome home health visits as an expression of personalized care; others may view inviting clinical personnel into the home as intrusive. Understanding these preferences enables sites to tailor outreach strategies that feel respectful rather than imposing.

By approaching patients with respect, equipping staff with cultural insight, and adapting materials to meet the needs of diverse populations, research teams create conditions in which more people feel seen, understood, respected, and able to participate. These steps do not eliminate all enrollment disparities, but they meaningfully shift the experience of engaging with clinical research, an essential prerequisite to improving representation in cardiology trials.

As trial protocols have grown more complex — and as daily life has become more demanding for many — the burden placed on patients participating in research has increased significantly. That burden has a direct effect on both enrollment and retention. Even small increases in visit frequency, time commitments, or travel requirements can discourage participation, and these pressures often fall unevenly across populations. For patients balancing work, caregiving responsibilities, limited transportation, and/or unstable income, the logistical challenges can be especially acute. High retention is essential for maintaining statistical power; when patients withdraw because participation becomes unmanageable, entire programs can be jeopardized.

To address these realities, the use of digital technologies in clinical studies has steadily expanded. Cardiology trials, long associated with intensive monitoring and frequent assessments, increasingly rely on telehealth appointments, digital questionnaires, wearable sensors, and remote data capture systems. Some studies now collect half of their data electronically, reducing the need for repeated site visits and creating a more flexible patient experience.

Digital tools, however, cannot be a one-size-fits-all solution. Many cardiovascular patients are in their 40s or older, and digital access varies widely across age groups, geographies, and socioeconomic backgrounds. Some patients lack smartphones or reliable Wi-Fi, while others are uncomfortable using apps or portals to complete study tasks. Sponsors and sites are therefore adopting hybrid models that preserve non-digital pathways. Paper-based options remain essential for patient-reported outcomes, and some trials provide cellular-enabled devices or subsidize data plans to ensure that technology itself does not become an exclusion factor.

Remote and home-based services complement these digital advances. Blood draws, blood pressure checks, simple lab procedures, and even medication delivery can now be arranged through home health providers, easing the burden on patients who would otherwise need to make multiple trips to a site each month. When thoughtfully planned, these services reduce travel costs, minimize time away from work, and help patients with mobility or comorbidity challenges remain active in the study.

In some regions, integrating clinical research into familiar healthcare settings, such as local general practitioners’ offices or community cardiology clinics, offers additional advantages. Patients may feel more comfortable receiving research-related care from clinicians they already know, and routine monitoring performed as part of standard medical visits can sometimes satisfy trial requirements. This model is not universally feasible, particularly where clinical workloads are already overwhelming, but it remains an important lever for reducing burden when local health systems can support it.

Ultimately, improving patient experience in cardiovascular research requires a mosaic of strategies. Digital tools, home services, and site-based accommodations each solve a different part of the problem. The most effective research organizations are those prepared to assemble and adapt these elements based on the specific needs of a study and the lived realities of the patients it seeks to serve.

There is growing recognition across global regulatory bodies that the scientific rigor of a clinical trial depends on enrolling participants who reflect the populations that will ultimately use the therapy. Even as some regions, particularly the United States, navigate shifting political landscapes around the fundamental concepts of diversity and inclusion, sponsors understand that representation is not simply a policy expectation but a scientific necessity. Regulators continue to encourage or require diversity planning, with many trials now incorporating explicit enrollment targets for sex, race, and ethnicity.

These expectations, however, are not uniform. Diversity requirements often vary by therapeutic area, geographic region, and individual study design. In cardiovascular research, some recent trials have included benchmarks, such as ensuring that 20–30% of participants are women, reflecting longstanding gender disparities in diagnosis and enrollment. Similar considerations are emerging for racial and ethnic minority groups, whose distinct genetic profiles, comorbidity patterns, and disease presentations can meaningfully influence therapeutic response.

Debate persists about whether diversity goals should be mandated or strongly recommended. A central concern is the unintended consequence of delaying or blocking approval of therapies that are safe and effective simply because certain populations are difficult to enroll. Policymakers have struggled to balance scientific validity with practical feasibility. Recent regulatory reversals in the United States illustrate this tension: while diversity frameworks were initially positioned as mandatory, they have since been softened to avoid making trial completion unattainable for conditions where certain populations are historically underrepresented.

Even with these uncertainties, the direction of progress is clear. Regulators expect sponsors and research organizations to demonstrate proactive, thoughtful strategies for reaching clinically relevant populations. Diversity planning has become an integral part of protocol development, feasibility assessments, and site engagement, reinforcing the idea that equitable representation is now a core element of trial quality, not an optional enhancement.

Real-world data (RWD) and real-world evidence (RWE) have become indispensable tools for designing more representative and clinically meaningful cardiovascular trials. By drawing on electronic health records (EHRs), claims data sets, disease registries, and other sources capturing routine medical practice, sponsors gain a clearer view of how cardiovascular conditions manifest across different populations, how comorbidities cluster, and where unmet needs are most acute. This information not only enriches scientific understanding but also supports more strategic choices in trial design.

One of the most immediate applications of RWD is feasibility planning. By analyzing where patients with specific diagnoses, risk factors, or genetic profiles actually receive care, sponsors can identify cities, regions, and countries with the highest concentrations of eligible participants. This helps ensure that trial sites are placed where patients truly are — rather than where enrollment has traditionally occurred — and can be particularly important for reaching populations historically underrepresented in cardiac research.

RWD also inform protocol construction in ways that directly affect inclusivity, enabling teams to understand:

• Which comorbidities are prevalent in certain groups

• How blood pressure, renal function, or glycemic control typically fluctuate across demographics

• Which lab thresholds would unintentionally exclude large segments of the real-world patient population

These insights allow sponsors to refine inclusion and exclusion criteria so that they are better aligned with the patients that clinicians see every day while remaining scientifically responsible. This alignment is especially important in cardiology, where conditions, such as obesity, diabetes, and chronic kidney disease, commonly intersect and disproportionately affect groups already underrepresented in research.

During protocol development, RWD support risk stratification and the selection of endpoints that are clinically meaningful and also realistic for diverse patient cohorts. They highlight differences in disease progression patterns, symptom burden, and treatment response across populations, insights that help ensure that the trial evaluates outcomes that matter to clinicians and patients alike.

While clinical trials must still maintain stricter oversight than real-world practice to ensure safety and data integrity, integrating RWD into early planning helps bridge the gap between investigational research and routine care. The result is trial designs that better anticipate patient needs, reduce unnecessary exclusion, and generate findings that are more applicable to the full spectrum of individuals affected by cardiovascular disease.

Cardiovascular disease rarely occurs in isolation. Many patients live with multiple chronic conditions — obesity, type 2 diabetes, chronic kidney disease, hypertension — that complicate both diagnosis and trial eligibility. These comorbidities are not evenly distributed across populations, and their presence can shape who ultimately qualifies for cardiovascular studies.

Obesity offers a clear example. It is more prevalent among patients with cardiac disease, yet many trials impose body mass index (BMI) caps intended to limit confounding variables or safety risks. These thresholds, while well intentioned, can exclude a sizeable portion of the very population most affected by the condition under study. Similar challenges arise with metabolic and renal parameters: strict cutoffs for HbA1c, blood pressure, creatinine, or estimated glomerular filtration rate often disqualify individuals with common, clinically managed comorbidities.

The impact of these criteria is particularly evident in patient groups that experience barriers to regular healthcare. In communities such as Afro-Caribbean and some South Asian populations — where cardiovascular risk is already 1.5–3 times higher than in white populations — engagement with routine primary and specialty care may be limited. Without consistent monitoring, conditions like hypertension or diabetes are more likely to be poorly controlled, increasing the likelihood that screening labs will fall outside protocol-defined ranges. As a result, individuals who carry a disproportionate burden of cardiovascular disease may be systematically excluded from research intended to improve outcomes for that very disease.

These dynamics underscore the need for thoughtful protocol design informed by real-world patient profiles. When eligibility thresholds reflect only idealized clinical values rather than the realities of everyday practice, they unintentionally narrow the study population and reduce the applicability of results. Addressing comorbidity challenges requires balancing scientific rigor with practical feasibility, ensuring that cardiovascular trials remain safe and meaningfully representative of the patients most likely to benefit from new therapies.

We bring more than four decades of operational and therapeutic experience to cardiovascular research, supported by a global network of wholly owned sites and home trial services. Our global network combines owned locations with partnered and affiliated practices, including integrated physician groups supported by on-site staff. This structure enables consistent standards of care while allowing trial operations to adapt to the needs of local patient communities.

At the core of our model is a simple progression: engage patients, empower them, and then enroll them. This sequence reflects the belief — reinforced across our cardiology sites — that representation and retention only happen when patients feel understood, respected, and confident in the care they receive. Every cardiovascular study is tailored not only to the therapeutic indication and procedural demands but also to the practical realities of the patient population it seeks to serve.

Selecting the right sites is central to that effort. Feasibility assessments examine a site’s operational capabilities, its access to specialized cardiology expertise, local disease prevalence, and historical performance metrics. These evaluations ensure that recommended sites are not only technically equipped but also positioned within communities where eligible patients live. Our blended network approach broadens this reach even further: affiliated sites extend access into rural or underserved regions, while urban centers often provide concentrated access to diverse patient groups. Identifying qualified patients who live near but may not be connected to traditional research hubs reduces travel burdens and makes participation more feasible for those balancing work, caregiving, comorbidities, or transportation constraints.

Our cardiology footprint is substantial. More than 55 global sites offer experience across heart failure, cardiomyopathies, arrhythmias, lipid disorders, and other cardiovascular conditions. These locations are supported by a broad network of partner cardiologists, including interventionalists and subspecialists, who serve as investigators or referral partners. Access to a proprietary database of patients with cardiovascular disease, associated risk factors, and comorbidities enhances the ability to conduct predictive modeling and feasibility planning. Importantly, the database includes race and ethnicity information for more than 10 million individuals, supporting diversity planning and enabling more precise enrollment projections.

Our operational model also responds to cultural considerations. Many sites cultivate relationships with local religious leaders and participate in community events to increase awareness among groups with elevated cardiovascular risk but historically low trial participation. Staff across the network receive ongoing training focused on cultural awareness and communication strategies that are respectful, appropriate, and adaptive to patient preferences. Embedding site personnel who come from the communities they serve further strengthens trust and comfort, especially for patients with higher clinical risk or limited prior engagement with research.

Finally, having trained and experienced physicians on site who understand the longitudinal experiences of cardiac patients — whether those patients are managing heart failure, living with complex comorbidities, or navigating diagnostic uncertainty — helps ensure that trial participation feels like an extension of their clinical care rather than an unfamiliar parallel process. This alignment not only improves patient experience but also delivers higher-quality data and more reliable retention over the course of the study.